株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

イネ科花粉症:パイプライン製品の分析

Grass Pollen Allergy - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 200453
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.14円で換算しております。
Back to Top
イネ科花粉症:パイプライン製品の分析 Grass Pollen Allergy - Pipeline Review, H1 2017
出版日: 2017年03月22日 ページ情報: 英文 43 Pages
概要

イネ科花粉アレルギーは、イネ科植物の花粉に接触してすぐに発生する反応のことを指します。主な症状・徴候には、皮膚の反応(じんましん・発赤・腫れなど)、口・喉の辺りのかゆみ・刺痛、喉の硬直、)、息切れ、喘鳴、鼻水などが挙げられます。主な疾病素質には年齢や家族歴、他のアレルギー体質などがあります。

当レポートでは、世界各国でのイネ科植物による花粉症の治療用パイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

イネ科花粉症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

イネ科花粉症:企業で開発中の治療薬

イネ科花粉症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品

イネ科花粉症:企業で開発中の製品

イネ科花粉症の治療薬開発に従事している企業

  • ALK-Abello A/S
  • Allergy Therapeutics Plc
  • Biomay AG
  • Circassia Pharmaceuticals Plc
  • HAL Allergy BV
  • Roxall Medizin GmbH
  • 塩野義製薬

イネ科花粉症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

イネ科花粉症:休止中のプロジェクト

イネ科花粉症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9083IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Grass Pollen Allergy - Pipeline Review, H1 2017, provides an overview of the Grass Pollen Allergy (Immunology) pipeline landscape.

Grass pollen allergy is a reaction which occurs soon after exposure to pollen from grasses. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Grass Pollen Allergy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Grass Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Grass Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II and Preclinical stages are 2, 3 and 2 respectively.

Grass Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Grass Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Grass Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Grass Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Grass Pollen Allergy (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Grass Pollen Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Grass Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Grass Pollen Allergy - Overview
  • Grass Pollen Allergy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Grass Pollen Allergy - Therapeutics Assessment
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Grass Pollen Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Allergy Therapeutics Plc
    • Biomay AG
    • HAL Allergy BV
  • Grass Pollen Allergy - Drug Profiles
    • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BM-32 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pollinex Quattro Grass - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine 1 for Grass Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Grass Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Grass Pollen Allergy - Dormant Projects
  • Grass Pollen Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Jan 26, 2017: Biomay AG Reports Positive Results From A Second Phase IIb Trial With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32
      • Sep 08, 2016: Grass pollen allergy vaccine also effective against hepatitis B
      • Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204
      • Jun 13, 2016: New Data From GAP Landmark Trial Confirm GRAZAX Prevents Asthma Symptoms in Children
      • Mar 04, 2016: Inflamax Research Announces the Successful Completion of Enrollment for the First Multi-center, Mobile Environmental Exposure Chamber (mEEC) Study
      • Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL
      • Jan 28, 2016: Biomay initiates new phase II clinical trial with grass pollen allergy vaccine BM32
      • Jan 14, 2016: ALK announces top-line results from the five-year landmark GRAZAX Asthma Prevention trial in children
      • Jun 03, 2015: Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference.
      • Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32
      • Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK
      • Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study
      • Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)
      • Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32
      • Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Grass Pollen Allergy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Grass Pollen Allergy - Pipeline by ALK-Abello A/S, H1 2017
  • Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H1 2017
  • Grass Pollen Allergy - Pipeline by Biomay AG, H1 2017
  • Grass Pollen Allergy - Pipeline by HAL Allergy BV, H1 2017
  • Grass Pollen Allergy - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Grass Pollen Allergy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top